<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ro">
	<id>https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=BIOXCEL_THERAPEUTICS_INC</id>
	<title>BIOXCEL THERAPEUTICS INC - Revizia istoricului</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=BIOXCEL_THERAPEUTICS_INC"/>
	<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=BIOXCEL_THERAPEUTICS_INC&amp;action=history"/>
	<updated>2026-04-17T11:11:24Z</updated>
	<subtitle>Istoricul versiunilor pentru această pagină din wiki</subtitle>
	<generator>MediaWiki 1.39.2</generator>
	<entry>
		<id>https://wiki.tradeville.ro/index.php?title=BIOXCEL_THERAPEUTICS_INC&amp;diff=410533&amp;oldid=prev</id>
		<title>Admin: Pagină nouă: Pagina dedicata companiei BIOXCEL THERAPEUTICS INC listata cu simbolul US.BTAI  ==Descriere companie== BioXcel Therapeutics, Inc. (http://www.bioxceltherapeutics.com/) is a clinical stage biopharmaceutical company. The Company is focused on drug development that utilizes artificial intelligence (AI) approaches to develop therapies in neuroscience and immuno-oncology. The Company's two advanced clinical development programs are BXCL501, an investigational, orally dissolving, s...</title>
		<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=BIOXCEL_THERAPEUTICS_INC&amp;diff=410533&amp;oldid=prev"/>
		<updated>2024-09-18T13:44:00Z</updated>

		<summary type="html">&lt;p&gt;Pagină nouă: Pagina dedicata companiei BIOXCEL THERAPEUTICS INC listata cu simbolul US.BTAI  ==Descriere companie== BioXcel Therapeutics, Inc. (http://www.bioxceltherapeutics.com/) is a clinical stage biopharmaceutical company. The Company is focused on drug development that utilizes artificial intelligence (AI) approaches to develop therapies in neuroscience and immuno-oncology. The Company&amp;#039;s two advanced clinical development programs are BXCL501, an investigational, orally dissolving, s...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Pagină nouă&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Pagina dedicata companiei BIOXCEL THERAPEUTICS INC listata cu simbolul US.BTAI&lt;br /&gt;
&lt;br /&gt;
==Descriere companie==&lt;br /&gt;
BioXcel Therapeutics, Inc. (http://www.bioxceltherapeutics.com/) is a clinical stage biopharmaceutical company. The Company is focused on drug development that utilizes artificial intelligence (AI) approaches to develop therapies in neuroscience and immuno-oncology. The Company's two advanced clinical development programs are BXCL501, an investigational, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine (Dex), for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment-naive to checkpoint inhibitors.&lt;br /&gt;
&lt;br /&gt;
==Grafic actiuni companie==&lt;br /&gt;
&amp;lt;iframe key=&amp;quot;tradeville&amp;quot; path=&amp;quot;graficSimbol/US.BTAI&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Ultimele stiri despre BIOXCEL THERAPEUTICS INC (US.BTAI)==&lt;br /&gt;
&amp;lt;dynamicpagelist&amp;gt;&lt;br /&gt;
category=US.BTAI&lt;br /&gt;
count=10&lt;br /&gt;
order=descending&lt;br /&gt;
addfirstcategorydate=false&lt;br /&gt;
&amp;lt;/dynamicpagelist&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Categorie:US.BTAI]][[Categorie:Stiri despre companii]]&lt;/div&gt;</summary>
		<author><name>Admin</name></author>
	</entry>
</feed>